Specific post-translational modifications of soluble tau protein distinguishes Alzheimer's disease and primary tauopathies.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
22 06 2023
Historique:
received: 05 12 2022
accepted: 07 06 2023
medline: 26 6 2023
pubmed: 23 6 2023
entrez: 22 6 2023
Statut: epublish

Résumé

Tau protein aggregates in several neurodegenerative disorders, referred to as tauopathies. The tau isoforms observed in post mortem human brain aggregates is used to classify tauopathies. However, distinguishing tauopathies ante mortem remains challenging, potentially due to differences between insoluble tau in aggregates and soluble tau in body fluids. Here, we demonstrated that tau isoforms differ between tauopathies in insoluble aggregates, but not in soluble brain extracts. We therefore characterized post-translational modifications of both the aggregated and the soluble tau protein obtained from post mortem human brain tissue of patients with Alzheimer's disease, cortico-basal degeneration, Pick's disease, and frontotemporal lobe degeneration. We found specific soluble signatures for each tauopathy and its specific aggregated tau isoforms: including ubiquitination on Lysine 369 for cortico-basal degeneration and acetylation on Lysine 311 for Pick's disease. These findings provide potential targets for future development of fluid-based biomarker assays able to distinguish tauopathies in vivo.

Identifiants

pubmed: 37349319
doi: 10.1038/s41467-023-39328-1
pii: 10.1038/s41467-023-39328-1
pmc: PMC10287718
doi:

Substances chimiques

tau Proteins 0
Lysine K3Z4F929H6
Protein Isoforms 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3706

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023. The Author(s).

Références

Front Neurol. 2022 Feb 08;12:786353
pubmed: 35211074
Curr Neurol Neurosci Rep. 2009 Sep;9(5):353-8
pubmed: 19664364
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Acta Neuropathol Commun. 2019 Dec 3;7(1):192
pubmed: 31796124
J Alzheimers Dis. 2022;88(1):207-228
pubmed: 35570492
EMBO Mol Med. 2020 Dec 7;12(12):e12921
pubmed: 33169916
Alzheimers Res Ther. 2020 Mar 17;12(1):26
pubmed: 32183883
Front Neurosci. 2020 Nov 04;14:581936
pubmed: 33250706
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552
pubmed: 34723319
Curr Opin Neurol. 2017 Dec;30(6):589-598
pubmed: 28914736
Front Aging Neurosci. 2019 May 21;11:121
pubmed: 31178717
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Nat Protoc. 2011 Feb;6(2):175-86
pubmed: 21293459
J Neurochem. 2008 Jun 1;105(6):2343-52
pubmed: 18315566
J Proteome Res. 2016 Feb 5;15(2):667-76
pubmed: 26742856
J Neuropathol Exp Neurol. 2012 May;71(5):362-81
pubmed: 22487856
Angew Chem Int Ed Engl. 2021 Jan 11;60(2):726-730
pubmed: 33017094
Cell. 2020 Feb 20;180(4):633-644.e12
pubmed: 32032505
Neurosci Lett. 2019 Jan 23;692:187-192
pubmed: 30423399
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Brain. 2021 Mar 3;144(2):515-527
pubmed: 33283854
Proteomics. 2018 Oct;18(20):e1800108
pubmed: 30230243
Brain. 2015 Sep;138(Pt 9):2716-31
pubmed: 26133663
J Alzheimers Dis. 2019;69(1):277-288
pubmed: 30958368
FEBS Lett. 2018 Jul;592(14):2383-2391
pubmed: 29790176
Trends Neurosci. 1998 Oct;21(10):428-33
pubmed: 9786340
Mol Cell Neurosci. 2019 Jun;97:18-33
pubmed: 30529601
Acta Neuropathol Commun. 2020 Aug 27;8(1):149
pubmed: 32854776
Curr Neurol Neurosci Rep. 2017 Sep;17(9):72
pubmed: 28785992
Brain Res Bull. 2016 Sep;126(Pt 3):238-292
pubmed: 27615390
J Vis Exp. 2017 Oct 24;(128):
pubmed: 29155708
Nature. 2021 Oct;598(7880):359-363
pubmed: 34588692
J Neurol. 2019 Sep;266(9):2304-2311
pubmed: 31179518
Nat Rev Drug Discov. 2007 Jun;6(6):464-79
pubmed: 17541419
Handb Clin Neurol. 2018;150:131-141
pubmed: 29496136
J Neurochem. 2012 Nov;123(3):396-405
pubmed: 22862741
Cell. 2022 Oct 13;185(21):3913-3930.e19
pubmed: 36198316
Biol Open. 2014 Jan 15;3(1):1-11
pubmed: 24429107
Neuron. 2018 Mar 21;97(6):1284-1298.e7
pubmed: 29566794
Neuron. 1989 Oct;3(4):519-26
pubmed: 2484340
Angew Chem Int Ed Engl. 2018 Mar 12;57(12):3246-3250
pubmed: 29314492
Handb Clin Neurol. 2017;145:355-368
pubmed: 28987182
Acta Neuropathol. 2016 Feb;131(2):267-280
pubmed: 26538150
J Mol Neurosci. 2022 Aug;72(8):1557-1571
pubmed: 35325356
Acta Neuropathol Commun. 2018 Jun 29;6(1):52
pubmed: 29958544
Front Cell Neurosci. 2018 Oct 09;12:338
pubmed: 30356756
Mol Cell Proteomics. 2021;20:100165
pubmed: 34673283
J Neural Transm (Vienna). 2005 Jun;112(6):813-38
pubmed: 15517432
Nat Med. 2022 Dec;28(12):2547-2554
pubmed: 36424467
Cell. 2020 Dec 10;183(6):1699-1713.e13
pubmed: 33188775
Nature. 2020 Apr;580(7802):283-287
pubmed: 32050258
Front Aging Neurosci. 2018 Apr 19;10:113
pubmed: 29725295
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1953-8
pubmed: 16446437
Nat Med. 2022 Sep;28(9):1965
pubmed: 36100683
Front Neurol. 2021 Jan 07;11:595532
pubmed: 33488497
Acta Neuropathol. 2017 May;133(5):731-749
pubmed: 28083634

Auteurs

Nathalie Kyalu Ngoie Zola (N)

Universite catholique de Louvain (UCLouvain) and Institute of Neuroscience (IONS), 1200, Brussels, Belgium.
Universite catholique de Louvain (UCLouvain) and de Duve Institute (DDUV), Protein Phosphorylation (PHOS), 1200, Brussels, Belgium.

Clémence Balty (C)

Universite catholique de Louvain (UCLouvain) and de Duve Institute (DDUV), Protein Phosphorylation (PHOS), 1200, Brussels, Belgium.

Sébastien Pyr Dit Ruys (S)

Universite catholique de Louvain (UClouvain) and Louvain Drug Research Institute (LDRI), Integrated Pharmacometrics, Pharmacogenomics and Pharmacokinetics Group (PMGK), 1200, Brussels, Belgium.

Axelle A T Vanparys (AAT)

Universite catholique de Louvain (UCLouvain) and Institute of Neuroscience (IONS), 1200, Brussels, Belgium.

Nicolas D G Huyghe (NDG)

Université catholique de Louvain (UCLouvain) and Institut de Recherche Expérimentale et Clinique (IREC), 1200, Brussels, Belgium.

Gaëtan Herinckx (G)

Universite catholique de Louvain (UCLouvain), de Duve Institute (DDUV), and MASSPROT Platform, 1200, Brussels, Belgium.

Manuel Johanns (M)

Universite catholique de Louvain (UCLouvain) and de Duve Institute (DDUV), Protein Phosphorylation (PHOS), 1200, Brussels, Belgium.

Emilien Boyer (E)

Universite catholique de Louvain (UCLouvain) and Institute of Neuroscience (IONS), 1200, Brussels, Belgium.
Cliniques universitaires Saint-Luc, Neurology Department, 1200, Brussels, Belgium.

Pascal Kienlen-Campard (P)

Universite catholique de Louvain (UCLouvain) and Institute of Neuroscience (IONS), 1200, Brussels, Belgium.

Mark H Rider (MH)

Universite catholique de Louvain (UCLouvain) and de Duve Institute (DDUV), Protein Phosphorylation (PHOS), 1200, Brussels, Belgium.

Didier Vertommen (D)

Universite catholique de Louvain (UCLouvain), de Duve Institute (DDUV), and MASSPROT Platform, 1200, Brussels, Belgium.

Bernard J Hanseeuw (BJ)

Universite catholique de Louvain (UCLouvain) and Institute of Neuroscience (IONS), 1200, Brussels, Belgium. bernard.hanseeuw@uclouvain.be.
Cliniques universitaires Saint-Luc, Neurology Department, 1200, Brussels, Belgium. bernard.hanseeuw@uclouvain.be.
Universite catholique de Louvain (UCLouvain), WELBIO department, WEL Research Institute, avenue Pasteur, 6, 1300, Wavre, Belgium. bernard.hanseeuw@uclouvain.be.
Harvard Medical School, Massachusetts General Hospital, Department of Radiology, Gordon Center for Medical Imaging, Boston, MA, USA. bernard.hanseeuw@uclouvain.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH